Bafna Pharmaceuticals Limited (NSE:BAFNAPH)

Market Cap	10.75B +187.0%
Revenue (ttm)	1.43B -3.1%
Net Income	77.86M -5.8%
EPS	3.24 -7.0%
Shares Out	23.66M
PE Ratio	140.10
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,172
Open	456.50
Previous Close	447.55
Day's Range	454.40 - 456.50
52-Week Range	94.77 - 479.95
Beta	-0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About Bafna Pharmaceuticals

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company offers its products in various dosage forms, including tablets, capsules, and solid orals. It provides various products for cardiovascular and hypertension, potent oncology, anti-infectives, central nervous system, and diabetic related diseases, as well as provision of contract research and manufacturing services. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, and Niger...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 339
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BAFNAPH

Financial Performance

In fiscal year 2026, Bafna Pharmaceuticals's revenue was 1.51 billion, an increase of 3.26% compared to the previous year's 1.46 billion. Earnings were 111.00 million, an increase of 167.30%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error